Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas

References

• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–566.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247–4253.
   PubMed Web of Science ®Google Scholar
• Conde E, Angulo B, Izquierdo E, et al. The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre. Histopathology. 2013;62:609–616.
   PubMed Web of Science ®Google Scholar
• Rossi G, Baldi L, Barbieri F, et al. Concomitant EGFR and KRAS mutations in ALK-rearranged lung cancer. Ann Oncol. 2015;26:1035–1036.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–550.
   PubMed Web of Science ®Google Scholar
• Riely GJ, Chaft JE, Ladanyi M, et al. Incorporation of crizotinib into the NCCN guidelines. J Natl Compr Can Netw. 2011;9:1328–1330.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. [cited 2013 Jul 21]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Public_assessment_report/human/002489/WC500134761.pdf
   Google Scholar
• Ventana launches first fully automated IHC companion diagnostic in Europe to identify ALK protein expression in lung cancer patients. [cited 2012 Oct 25]. Available from: http://www.ventana.com/site/page?view=press-release-oct25-2012.
   Google Scholar
• Food and Drug Administration. Available from: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm454476.htm
   Google Scholar
• Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370:1189–1197.
   PubMed Web of Science ®Google Scholar
• Khozin S, Blumenthal GM, Zhang L, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res. 2015;21:2436–2439.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Sherman CA, Willoughby K, et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 2015;10:232–236.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016;17:234–242.
   Web of Science ®Google Scholar
• Ou SI, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol. 2016;34:661–668.
   PubMed Web of Science ®Google Scholar
• Zou HY, Friboulet L, Kodack DP, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell. 2015;28:70–81.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med. 2016;374:54–61.
   PubMed Web of Science ®Google Scholar
• Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013;137:828–860.
   PubMed Web of Science ®Google Scholar
• NCCN clinical practice guidelines in oncology – non-small cell lung cancer version 7. 2015. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
   Google Scholar
• Felip E, Concha Á, de Castro J, et al. Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2015;17:103–112.
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Togashi Y, Kamihara Y, et al. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study). Ann Oncol. 2016;27:185–192.
   PubMed Web of Science ®Google Scholar
• Conde E, Suárez-Gauthier A, Benito A, et al. Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. PLoS One. 2014;9:e107200.
   PubMed Web of Science ®Google Scholar
• Yatabe Y. ALK FISH and IHC: you cannot have one without the other. J Thorac Oncol. 2015;10:548–550.
   PubMed Web of Science ®Google Scholar
• Li Y, Pan Y, Wang R, et al. ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. PLoS One. 2013;8:e69016.
   PubMed Web of Science ®Google Scholar
• Takeuchi K. Interpretation of anti-ALK immunohistochemistry results. J Thorac Oncol. 2013;8:e67–e68.
   PubMed Web of Science ®Google Scholar
• Takanashi Y, Tajima S, Matsuura S, et al. ALK-rearranged squamous cell carcinoma of the lung. Respirol Case Rep. 2015;3:105–107.
   PubMedGoogle Scholar
• Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res. 2015;21:2227–2235.
   PubMed Web of Science ®Google Scholar
• von Laffert M, Warth A, Penzel R, et al. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. J Thorac Oncol. 2014;9:1685–1692.
   PubMed Web of Science ®Google Scholar
• Murakami Y, Mitsudomi T, Yatabe Y. A screening method for the ALK fusion gene in NSCLC. Front Oncol. 2012;2:24.
   PubMedGoogle Scholar
• Nakamura H, Tsuta K, Yoshida A, et al. Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma. J Clin Pathol. 2013;66:705–707.
   PubMed Web of Science ®Google Scholar
• Conde E, Angulo B, Izquierdo E, et al. Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers. Clin Transl Oncol. 2013;15:503–508.
   PubMed Web of Science ®Google Scholar
• Paik JH, Choe G, Kim H, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol. 2011;6:466–472.
   PubMed Web of Science ®Google Scholar
• Sholl LM, Weremowicz S, Gray SW, et al. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol. 2013;8:322–328.
   PubMed Web of Science ®Google Scholar
• Kim H, Xu X, Yoo SB, et al. Discordance between anaplastic lymphoma kinase status in primary non-small-cell lung cancers and their corresponding metastases. Histopathology. 2013;62:305–314.
   PubMed Web of Science ®Google Scholar
• Conde E, Taniere P, Lopez-Rios F. The anaplastic lymphoma kinase testing conundrum. Expert Rev Mol Diagn. 2015;15:161–163.
   PubMed Web of Science ®Google Scholar
• Savic S, Diebold J, Zimmermann AK, et al. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. Lung Cancer. 2015;89:104–109.
   PubMed Web of Science ®Google Scholar
• Gao X, Sholl LM, Nishino M, et al. Clinical implications of variant ALK FISH rearrangement patterns. J Thorac Oncol. 2015;10:1648–1652.
   PubMed Web of Science ®Google Scholar
• Jiang L, Yang H, He P, et al. Improving selection criteria for ALK inhibitor therapy in non-small cell lung cancer: a pooled-data analysis on diagnostic operating characteristics of immunohistochemistry. Am J Surg Pathol. [Epub ahead of print].
   Google Scholar
• Conklin CM, Craddock KJ, Have C, et al. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol. 2013;8:45–51.
   PubMed Web of Science ®Google Scholar
• Selinger CI, Rogers TM, Russell PA, et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2013;26:1545–1553.
   PubMed Web of Science ®Google Scholar
• Hutarew G, Hauser-Kronberger C, Strasser F, et al. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH. Histopathology. 2014;65:398–407.
   PubMed Web of Science ®Google Scholar
• Rogers TM, Russell PA, Wright G, et al. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer. J Thorac Oncol. 2015;10:611–618.
   PubMed Web of Science ®Google Scholar
• Sacher AG, Dahlberg SE, Heng J, et al. Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer. JAMA Oncol. 2016;2:313–320.
   Google Scholar